HGH Fragment 176-191 Overview
Category:
Peptide
How It Works:
Stimulates fat breakdown and inhibits fat creation by mimicking growth hormone’s lipolytic signals without broad hormonal effects.
Alternative Names:
HGH Frag 176-191; C-terminal GH fragment
Primary Research Focus:
- Adipose metabolism
- Obesity and body composition science
Potential Risks:
No FDA approval; limited human clinical data; unknown long-term effects
What It Is
HGH Fragment 176-191 is a synthetic peptide composed of the C-terminal segment (amino acids 176–191) of human growth hormone (HGH). This small fragment retains only the fat-metabolism signaling portion of the full hormone — designed to separate fat-burning effects from growth-promoting actions like cell proliferation or high IGF-1 production.
In research models, it’s used to explore how targeted pathways can influence adipose tissue without broad HGH activity.
How It Works In the Body
Rather than activating classic HGH receptors throughout the body, Fragment 176-191 targets fat tissue pathways to:
- Stimulate lipolysis — the breakdown of stored triglycerides into free fatty acids and glycerol.
- Inhibit lipogenesis — the creation of new fat stores.
- Activate beta-3 adrenergic signaling in adipocytes (fat cells) which can increase fat liberation for energy use.
- Potentially enhance metabolic rate and thermogenesis.
This selective action appears to avoid many systemic hormonal effects tied to full HGH use, such as elevated IGF-1 or insulin resistance — at least in short-term studies.
HGH Fragment 176-191 Benefits
Targeted Fat Reduction
HGH Fragment 176-191 is best known for enhancing fat breakdown (lipolysis) and reducing new fat formation (lipogenesis) in animal and in vitro models. Studies in obese rodents indicate increased thermogenesis and weight loss without sacrificing lean mass or significantly altering glucose levels.
Metabolic Modulation
Through activation of adipocyte signaling, the peptide may support higher energy expenditure and fat-to-fuel conversion — a mechanism researchers view as promising for metabolic studies.
Lean Mass Preservation
Unlike full growth hormone therapy, this fragment appears to spare muscle tissue while focusing on adipose tissue, making it a point of interest in body-recomposition research.
Minimal Hormonal Disruption
In research and limited clinical studies (often involving AOD-9604 analogues), Fragment 176-191 doesn’t seem to raise IGF-1, disrupt glucose homeostasis, or trigger broad endocrine changes tied to traditional HGH treatments.
Cartilage & Joint Potential
Preclinical research findings (e.g., rabbit models combining hyaluronic acid with the peptide) suggest possible benefits in cartilage regeneration, although human evidence is lacking.
Clinical Studies
Although the fragment has been studied in multiple trials, the evidence in humans is extremely limited and often related to analogues like AOD-9604 rather than the unmodified peptide itself. Some key takeaways:
- Several early phase trials explored safety and metabolic outcomes at doses up to 400 µg/kg without notable changes in IGF-1, glucose tolerance, insulin resistance, or cardiovascular parameters compared with placebo.
- Reported mild effects in these settings included headaches and transient localized reactions.
Importantly, controlled, large-scale human trials validating weight loss efficacy are still lacking; much of the fat-loss data comes from animal studies.
Safety, Side Effects, and Considerations
Safety Profile
- Fragment 176-191 has not undergone the rigorous clinical testing needed for regulatory approval.
- What exists largely comes from animal models or analogues like AOD-9604, which may not fully reflect the unmodified fragment’s behavior.
Side Effects
Reported effects are generally mild or temporary in the small clinical data available and include:
- Headache
- Injection site discomfort
- Fatigue or mild nausea
- Occasional transient metabolic signals in some animal studies
Unknowns & Risks
- Long-term safety is unknown due to a lack of extended human studies.
- Potential glucose metabolism changes have been suggested in some older peptide fragment research, though data is mixed.
- Unregulated quality and purity of commercially sourced peptides raise contamination and handling concerns.
Regulatory Status
HGH Fragment 176-191 is not approved by the FDA for human therapeutic use. Its sale and administration for weight loss or performance purposes fall outside legal medical indications in many jurisdictions.
Bottom Line
HGH Fragment 176-191 is a promising tool in fat-metabolism research, known to enhance lipolysis and reduce lipogenesis in laboratory and animal studies — without the broad endocrine effects seen with full HGH. However, human evidence of meaningful benefits and long-term safety is currently insufficient, and available data mainly arises from small, short-term investigations or analogues related to the peptide.
Researchers interested in targeted adipose signaling may find Fragment 176-191 mechanistically appealing, but clinical use outside controlled studies remains unverified and unapproved.
